According to filings with the U.S. Securities and Exchange Commission, CoRegen is raising up to $13,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About CoRegen
Advancing life-changing therapies with innovation and purpose. Our mission is to pioneer next-generation treatments that eliminate a wide range of deadly cancers and redefine whats possible in modern medicine. Through relentless research, cutting-edge biotechnology, and an unwavering commitment to patients, we are reshaping the future of cancer healthcare. CoRegen is founded on these key principles.

To learn more about CoRegen, visit https://www.coregen.com/
CoRegen Linkedin Page: https://www.linkedin.com/company/coregen-inc/

Contact:
Sonja Nelson, Chief Financial Officer
858-232-5241
https://www.linkedin.com/in/sonja-nelson-3a49783/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.